Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer.
Journal Article (Journal Article)
Clinical resistance to the second-generation antiandrogen enzalutamide in castration-resistant prostate cancer (CRPC), despite persistent androgen receptor (AR) activity in tumors, highlights an unmet medical need for next-generation antagonists. We have identified and characterized tetra-aryl cyclobutanes (CBs) as a new class of competitive AR antagonists that exhibit a unique mechanism of action. These CBs are structurally distinct from current antiandrogens (hydroxyflutamide, bicalutamide, and enzalutamide) and inhibit AR-mediated gene expression, cell proliferation, and tumor growth in several models of CRPC. Conformational profiling revealed that CBs stabilize an AR conformation resembling an unliganded receptor. Using a variety of techniques, it was determined that the AR-CB complex was not recruited to AR-regulated promoters and, like apo AR, remains sequestered in the cytoplasm, bound to heat shock proteins. Thus, we have identified third-generation AR antagonists whose unique mechanism of action suggests that they may have therapeutic potential in CRPC.
- Pollock, JA; Wardell, SE; Parent, AA; Stagg, DB; Ellison, SJ; Alley, HM; Chao, CA; Lawrence, SA; Stice, JP; Spasojevic, I; Baker, JG; Kim, SH; McDonnell, DP; Katzenellenbogen, JA; Norris, JD
- October 2016
Volume / Issue
- 12 / 10
Start / End Page
- 795 - 801
Pubmed Central ID
Electronic International Standard Serial Number (EISSN)
Digital Object Identifier (DOI)
- United States